Antibiotics and the burn patient

Burns

Volumn 37, Issue 1, 2011, Pages 16-26

  Ravat, François ^a   Le Floch, Ronan ^b   Vinsonneau, Christophe ^c   Ainaud, Pierre ^d   Bertin Maghit, Marc ^e   Carsin, Hervé ^f   Perro, Gérard ^g  

^a CENTRE HOSPITALIER SAINT JOSEPH SAINT LUC   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c Institut Cochin   (France)

^d HÔPITAL DE LA CONCEPTION   (France)

^e EDOUARD HERRIOT HOSPITAL   (France)

^f PERCY MILITARY HOSPITAL   (France)

^g HÔPITAL PELLEGRIN   (France)

Author keywords

Antibiotic therapy; Antibiotics; Bacterial resistance; Burn; Burn patient; Dosage; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BACTERICIDE; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTRIAXONE; CIPROFLOXACIN; CLOXACILLIN; DORIPENEM; ERTAPENEM; FOSFOMYCIN; OXACILLIN; PEFLOXACIN; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BURN INFECTION; BURN PATIENT; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG MONITORING; HUMAN; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; PRACTICE GUIDELINE; REVIEW; TREATMENT DURATION;

ANTI-BACTERIAL AGENTS; BURNS; HUMANS; PRACTICE GUIDELINES AS TOPIC; WOUND INFECTION;

EID: 78650521479     PISSN: 03054179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.burns.2009.10.006     Document Type: Review

References (79)

1. D.L. Sackett, S.E. Straus, W.S. Richardson, W. Rosenberg, and R.B. Haynes Evidence-based medicine: how to practice and teach EBM second ed. 2000 Churchill Livingstone London
2. C. Delvenne, and F. Pasleau Comment résoudre en pratique un problme diagnostique ou thérapeutique en suivant une démarche EBM? Rev Med Liege 55 2000 226 232
3. M.H. Kollef Is there a role for antibiotic cycling in the intensive care unit? Crit Care Med 28 Suppl. 4 2001 N135 N142
4. D.A. Goldmann, R.A. Weinstein, R.P. Wenzel, O.C. Tablan, R.J. Dumas, and R.P. Gaynes Strategies to prevent and control the emergence and spread of antimicrobial resistant microorganisms in hospitals: a challenge to hospital leadership JAMA 275 1996 234 240
5. Haute Autorité de Santé. Recommandations professionnelles: stratégies d'antibiothérapie et prévention des résistances bactériennes en établissement de santé; Avril 2008. www.has.fr.
6. J. Latarjet, and C. Echinard Les brûlures 1993 Masson Paris
7. J.P. Heggers, H. Hawkins, P. Edgar, C. Villareal, and D. Herndon Treatment of infection in burns D.H. Herndon, Total burn care second ed. 2002 WB Saunders London 120 169
8. E.R. Sherwood, and D.L. Traber The systemic inflammatory response syndrome D.H. Herndon, Total burn care 3rd ed 2007 Saunders-Elsevier 293 309
9. M.G. Jeschke, R.P. Mlcak, C.C. Finnerty, W.B. Norbury, G.G. Gauglitz, and G.A. Kulp Burn size determines the inflammatory and hypermetabolic response Crit Care Med 35 Suppl. 2007 S519 S523
10. A.O. Ugburo, O.A. Atoyebi, J.O. Oyeneyin, and G.O.A. Sowemimo An evaluation of the role of systemic antibiotic prophylaxis in the control of burn wound infection at the Lagos University Teaching Hospital Burns 30 2004 43 48
11. Conférence d'experts de la SFAR (Société Franaise d'Anesthésie et de Réanimation). Associations d'antibiotiques ou monothérapie en réanimation chirurgicale et en chirurgie; 1999. www.sfar.org.
12. Antibiothérapie probabiliste des états septiques, graves Ann Fr Anesth Reanim 23 2004 1020 1026
13. A. Lepape Epidémiologie et écologie bactérienne des infections nosocomiales en réanimation C. Martin, F. Gouin, Infections et antibiothérapie en réanimation aux urgences et en chirurgie 2000 Arnette Paris 427 439
14. J.N. Greene The microbiology of colonization, including techniques for assessing and measuring colonization Infect Contl Hosp Epidemiol 17 1996 114 118
15. M.J. Bonten, and R.A. Weinstein The role of colonization in the pathogenesis of nosocomial infections Infect Contl Hosp Epidemiol 17 1996 193 200
16. R.P. Dellinger, J.M. Carlet, H. Masur, H. Gerlach, T. Calandra, and J. Cohen Surviving. Sepsis Campaign guidelines for management of severe sepsis and septic shock Intensive Care Med 30 2004 536 555 (Pubitemid 38541501)
17. A. Kumar, D. Roberts, K.E. Wood, B. Light, J.E. Parrillo, and S. Sharma Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock Crit Care Med 34 2006 1589 1596
18. C.M. Luna, P. Vujacich, M.S. Niederman, C. Vay, C. Gherardi, and J. Matera Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia Chest 111 1997 676 685 (Pubitemid 27132946)
19. M. Iregui, S. Ward, G. Sherman, V.J. Fraser, and M.H. Kollef Clinical importance of delays in the initiation of appropriate treatment for ventilator-associated pneumonia Chest 122 2002 262 268
20. M.H. Kollef, and S.T. Micek Strategies to prevent antimicrobial resistance in the intensive care unit Crit Care Med 33 2005 1845 1853
21. A.M. Munster The immunological response and strategies for intervention D.H. Herndon, Total burn care second ed. 2002 WB Saunders London 316 330
22. X. Zhao, and K. Drlica Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolones studies Clin Infect Dis 33 Suppl. 3 2001 S147 S156
23. C. Brun-Buisson Associations d'antibiotiques ou monothérapie? Actualités en Réanimation et Urgences 2007 Elsevier Masson Paris pp. 463-473
24. N. Safdar, J. Handelsman, and D.G. Maki Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis Lancet Infect Dis 4 2004 519 527
25. B. Blanchet, V. Julien, C. Vinsonneau, and M. Tod Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients Clin Pharmacokinet 47 2008 635 654
26. A. Lesne-Hulin, P. Bourget, F. Ravat, C. Goudin, and J. Latarjet Clinical pharmacokinetics of ciprofloxacin in patients with major burns Eur J Clin Pharmacol 55 1999 515 519 (Pubitemid 29446552)
27. J. Rello, L. Vidaur, A. Sandiumenge, A. Rodriguez, B. Gualis, and C. Boque De-escalation therapy in ventilator-associated pneumonia Crit Care Med 32 2004 2183 2190
28. G. Hoffken, and M.S. Niederman Nosocomial pneumonia: the importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU Chest 122 2002 21483 22196
29. H. Dupont, H. Mentec, J.P. Sollet, and G. Bleichner Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia Intensive Care Med 27 2001 355 362
30. M.H. Kollef Optimizing antibiotic therapy in the intensive care unit setting Crit Care 5 2001 189 195
31. M.H. Kollef Gram negative bacterial resistance: evolving patterns and treatment paradigms Clin Inf Dis 40 Suppl. 2 2005 S85 88
32. S.T. Micek, T.J. Heuring, J.M. Hollands, R.A. Shah, and M.H. Kollef Optimizing antibiotic treatment for ventilator-associated pneumonia Pharmacotherapy 26 2 2006 204 213
33. M.H. Kollef, and K.E. Kollef Antibiotic utilization and outcomes for patients with clinically suspected ventilator-associated pneumonia and negative quantitative BAL culture results Chest 128 2005 2706 2713
34. A. Forrest, D.E. Nix, C.H. Ballow, T.F. Goss, M.C. Birmingham, and J.J. Schentag Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients Antimicrob Agents Chemother 37 1993 1073 1081
35. J. Chastre, M. Wolff, J.Y. Fagon, S. Chevret, F. Thomas, and D. Wermert Comparison of 8 vs 15 days of antibiotic therapy for ventilator associated pneumonia in adults: a randomized trial JAMA 290 2003 2588 2598
36. M. Christ-Crain, D. Stolz, R. Bingisser, C. Müller, D. Miedinger, and P.R. Huber Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial Am J Respir Crit Care Med 174 1 2006 84 93
37. Guidelines for the management of adults with hospital-acquired ventilator-associated and healthcare-associated, pneumonia Am J Resp Crit Care Med 171 2005 388 416
38. G. Potel, J. Caillon, C. Jacqueline, D. Navas, M.F. Kergueris, and E. Batard Dosage des antibiotiques en réanimation: quand et comment demander et interpréter les tests Réanimation 15 2006 187 192
39. M.J. Weinbren Pharmacokinetics of antibiotics in burn patients J Antimicrob Chemother 44 1999 319 327
40. D.E. Zaske, R.J. Sawchuk, D.R. Gerding, and R.G. Strate Increased dosage requirements of gentamycin in burn patients J Trauma 6 1976 824 828
41. P. Bourget, A. Lesne-Hulin, R. Le Reveillé, H. Le Bever, and H. Carsin Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection Antimicrob Agents Chemother 40 1996 139 145
42. J.M. Conil, B. Georges, A. Breden, C. Segonds, M. Lavit, and T. Seguin Increased amikacin dosage requirements in burn patients receiving a once-daily regimen Int J Antimicrob Agents 28 2006 226 230
43. T.H. Kiser, D.W. Hoody, M.D. Obritsch, C.O. Wegzyn, P.C. Bauling, and D.N. Fish Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury Antimicrob Agents Chemother 50 2006 1937 1945
44. J.F. Mohr 3rd, L. Ostrosky-Zeichner, D.J. Wainright, D.H. Parks, T.C. Hollenbeck, and C.D. Ericsson Pharmacokinetic evaluation of single-dose intravenous daptomycin in patients with thermal burn injury Antimicrob Agents Chemother 52 2008 1891 1893
45. W. Craig Does the dose matter? Clin Infect Dis 33 Suppl. 3 2001 S233 S237
46. J.A. Roberts, P. Kruger, D.L. Paterson, and J. Lipman Antibiotic resistance - what's dosing got to do with it? Crit Care Med 36 2008 2433 2440
47. O. Petitjean, P. Nicolas, and M. Tod Pharmacodynamie des antibiotiques C. Martin, F. Gouin, Infections et antibiothérapie en réanimation aux urgences et en chirurgie 2000 Arnette Paris 13 82
48. B. Vogelman, and W.A. Craig Kinetics of antimicrobial activity J Pediatr 108 1986 835 840
49. J.M. Hyatt, P.S. Mckinnon, G.S. Zimmer, and J.J. Schentag The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents Clin Pharmacokinet 28 1995 143 160
50. R.D. Moore, P.S. Lietman, and C.R. Smith Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration J infect Dis 155 1987 93 99
51. P.E. Marik Aminoglycoside volumer of distribution and illness severity in clinically ill patients Anesth intensive Care 21 1993 172 173
52. M. Barza, J.P. Ioannidis, J.C. Cappelleri, and J. Lau Single or multiple daily doses of aminoglycosides: a meta-analysis BMJ 312 1996 338 345 (Pubitemid 26049400)
53. J. Lipman, J. Scribante, A.G. Gous, H. Hon, S. Tshukutsoane The Baragwanath Ciprofloxacin Study Group Pharmacokinetics profiles of high dose intravenous ciprofloxacin in severe sepsis Antimicrob Agents Chemother 42 1998 2235 2239
54. J.K. Thomas, A. Forrest, S.M. Bhavnani, J.M. Hyatt, A. Cheng, and C.H. Ballow Pharmacodynamics evaluation of factor associated with the development of bacterial resistance in acutely ill patients during therapy Antimicrob Agents Chemother 42 1998 521 527
55. J. Schentag Pharmacokinetic and pharmacodynamic surrogate markers: studies with fluoroquinolones in patients Am J Health-Syst Pharm 56 Suppl. 3 1999 S21 S24
56. W.A. Craig Pharmacokinetics/pharmacodynamics parameters: rationale for antimicrobial dosing of men and mice Clin Infect Dis 26 1998 1 12
57. M. Manduru, L.B. Mihm, R.L. White, L.W. Friedrich, R.A. Flume, and J.A. Bosso In vitro pharmacodynamics of ceftazidime against P. aeruginosa isolates from cystic fibrosis patients Antimicrob Agents Chemother 41 1997 2053 2056
58. M. Wysocki, F. Delatour, F. Faurisson, A. Rauss, Y. Pean, and B. Misset Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomised study Antimicrob Agents Chemother 45 2001 2460 2467
59. R. Garaffo Bases pharmacodynamiques de l'administration IV des beta lactamines par perfusion continue: optimisation de l'activité antibactérienne sur les bacilles gram négatif Antibiotics 4 2002 22 27
60. E. Viaene, H. Chanteux, H. Servais, M.P. Mingeot - Leclerc, and P. Tulkens Comparative stability of antipseudomonal agents administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor operated syringes (intensive care units) Antimicrob Agents Chemother 8 2002 2327 2332
61. D. Swanson, C. De Angelis, I. Smith, and J. Schentag Degradation kinetics of imipenem in normal saline and in human serum Antimicrob Agents Chemother 5 1986 936 937
62. F. Scaglione Can PK/PD be used in everyday clinical practice Int J Antimicrob Agents 19 2002 349 353
63. N. Frimodt-Moller How predictive is PK/PD for antibacterial agents? Int J Antimicrob Agents 19 2002 333 339
64. J. Carlet, and A. Tabah Antibiotherapie des etats infectieux graves Med Mal Infect 36 2006 299 303
65. A. Bolmstrom Determination of minimum bactericidal concentrations, kill curves, and postantibiotic effects with the E-test technology Diagn Microbiol Infect Dis 19 1994 187 195
66. J.A. Griswold, B.J. Grube, L.H. Engrav, J.A. Marvin, and D.M. Heimbach Determinants of donor sites infections in small burn grafts J Burn Care Rehabil 10 1989 531 535
67. P. Piel, S. Scarnati, W. Goldfarb, and H. Slater Antibiotics prophylaxis in patients undergoing burn wound excision J Burn Care Rehabil 6 1985 422 424
68. Recommandations pour la pratique de l'antibioprophylaxie en chirurgie Ann Fr Anesth Reanim 18 1999 75 85
69. H. Eagle, R. Fleishman, and M. Levy «Continuous» vs «discontinuous» therapy with penicillin: the effect of the interval between injections on therapeutic efficacy N Engl J Med 12 1953 481 488
70. W. Craig, and S. Ebert Continuous infusion of beta-lactam antibiotics Antimicrob Agents Chemother 36 1992 2577 2583
71. J. Mouton, and A. Vinks Is continuous infusion of beta lactam antibiotics worthwhile? Efficacy and pharmacokinectic considerations J Antimicrob Chemother 38 1996 5 15
72. K. Leder, J. Turnidge, T. Korman, and L. Grayson The clinical efficacy of continuous infusion flucloxacillin in serious staphylococcal sepsis J Antimicrob Chemother 43 1999 113 118
73. J.A. Roberts, J. Paratz, E. Paratz, W.A. Krueger, and J. Lipman Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role Int J Antimicrob Agents 30 2007 11 18
74. H. Lode, K. Borner, and P. Koeppe Pharmacodynamics of fluoroquinolones CID 27 1998 33 39
75. J.C. Garrelts, G. Jost, S.F. Kowalsky, G.J. Krol, and J.T. Lettieri Ciprofloxacin pharmacokinetics in burn patients Antimicrob Agents Chemother 40 1996 1153 1156
76. A.P. Johnson, M. Warren, and D.M. Livermore Activity of linezolid against multi resistant Gram-positive bacteria from diverse hospitals in the UK J Antimicrob Chemother 45 2000 225 230
77. T. Whitehouse, J.A. Cepeda, R. Shulman, L. Aarons, R. Nalda-Molina, and C. Tobin Pharmacokinetic studies of linezolid and teicoplanin in the critically ill J Antimicrob Chemother 55 2005 333 340
78. C. Adembri, S. Fallani, M.I. Cassetta, S. Arrigucci, A. Ottaviano, and P. Pecile Linezolid pharmacokinetic-pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion Int J Antimicrob Agents 31 2008 122 129
79. A.M. Lovering, R. Le Floch, L. Hovsepian, J. Stephanazzi, P. Bret, and G. Birraux Pharmacokinetic evaluation of linezolid in patients with major thermal injuries J Antimicrob Chemother 2009 [Epub ahead of print]